Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity of BNT162b2 vaccination and attitudes toward COVID-19 booster vaccines in Thai children
TCTR20220301002Completed
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoint: Long-term immunogenicity. Started Mar 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220301002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220301002.